Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction FOLFIRINOX and radiochemotherapy in locally advanced pancreatic adenocarcinoma
2016-000696-25Phase 2Completed
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Jun 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan, fluorouracil, folinic acid and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Feasibility. Started Jun 2021; status: completed.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acidgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2016-000696-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000696-25.